Cargando…

Which Cognitive Domains are Improved by Treatment with Vortioxetine?

BACKGROUND: These post hoc analyses evaluated vortioxetine efficacy on cognitive dysfunction in depression. Data were from a double-blind, randomized, fixed-dose, placebo-controlled, 8-week depression study in adults aged 18–65 years (n = 602) with DSM-IV–defined major depressive disorder (MDD). Sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, John E, Lophaven, Søren, Olsen, Christina K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091828/
https://www.ncbi.nlm.nih.gov/pubmed/27231256
http://dx.doi.org/10.1093/ijnp/pyw054
_version_ 1782464639566610432
author Harrison, John E
Lophaven, Søren
Olsen, Christina K
author_facet Harrison, John E
Lophaven, Søren
Olsen, Christina K
author_sort Harrison, John E
collection PubMed
description BACKGROUND: These post hoc analyses evaluated vortioxetine efficacy on cognitive dysfunction in depression. Data were from a double-blind, randomized, fixed-dose, placebo-controlled, 8-week depression study in adults aged 18–65 years (n = 602) with DSM-IV–defined major depressive disorder (MDD). Subjects were randomized (1:1:1) to vortioxetine 10mg/day or 20mg/day or placebo. METHODS: Cognitive function was assessed at baseline, Week 1 (10mg/day only) and Week 8 using Digit Symbol Substitution Test (DSST) number of correct symbols, Rey Auditory Verbal Learning Test, Trail Making Test, Stroop test, Simple Reaction Time, and Choice Reaction Time tests. The cognition variables were standardized and used for constructing composite Z-scores for the cognitive domains of executive function, attention/speed of processing, and memory. RESULTS: At Week 1, vortioxetine 10mg/day separated from placebo for attention/speed of processing (standardized composite Z-score = 0.21; p = 0.0238) and DSST number of correct symbols (standardized effect size = 0.18; p = 0.0458) and for executive function (standardized composite Z-score = 0.20; p = 0.0274). At Week 8, vortioxetine 10mg/day and 20mg/day separated from placebo for executive function and attention/speed of processing, with standardized composite Z-scores ranging from 0.35 to 0.49 (all p < 0.01). Standardized composite Z-scores for memory were 0.31 (p = 0.0036, 10mg/day) and 0.22 (p = 0.0349, 20mg/day). Standardized effect sizes for DSST were 0.51 (p < 0.0001, 10mg/day) and 0.52 (p < 0.0001, 20mg/day). Results are limited by the post hoc nature of the analyses and the absence of an active reference in the original study. CONCLUSIONS: Vortioxetine (10 and 20mg/day) had a multi-domain beneficial effect on cognitive performance, as evidenced by improvements in measures of executive function, attention/speed of processing, and memory. The effect on the DSST may be due to improvements in several cognitive skills.
format Online
Article
Text
id pubmed-5091828
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-50918282016-11-03 Which Cognitive Domains are Improved by Treatment with Vortioxetine? Harrison, John E Lophaven, Søren Olsen, Christina K Int J Neuropsychopharmacol Regular Research Article BACKGROUND: These post hoc analyses evaluated vortioxetine efficacy on cognitive dysfunction in depression. Data were from a double-blind, randomized, fixed-dose, placebo-controlled, 8-week depression study in adults aged 18–65 years (n = 602) with DSM-IV–defined major depressive disorder (MDD). Subjects were randomized (1:1:1) to vortioxetine 10mg/day or 20mg/day or placebo. METHODS: Cognitive function was assessed at baseline, Week 1 (10mg/day only) and Week 8 using Digit Symbol Substitution Test (DSST) number of correct symbols, Rey Auditory Verbal Learning Test, Trail Making Test, Stroop test, Simple Reaction Time, and Choice Reaction Time tests. The cognition variables were standardized and used for constructing composite Z-scores for the cognitive domains of executive function, attention/speed of processing, and memory. RESULTS: At Week 1, vortioxetine 10mg/day separated from placebo for attention/speed of processing (standardized composite Z-score = 0.21; p = 0.0238) and DSST number of correct symbols (standardized effect size = 0.18; p = 0.0458) and for executive function (standardized composite Z-score = 0.20; p = 0.0274). At Week 8, vortioxetine 10mg/day and 20mg/day separated from placebo for executive function and attention/speed of processing, with standardized composite Z-scores ranging from 0.35 to 0.49 (all p < 0.01). Standardized composite Z-scores for memory were 0.31 (p = 0.0036, 10mg/day) and 0.22 (p = 0.0349, 20mg/day). Standardized effect sizes for DSST were 0.51 (p < 0.0001, 10mg/day) and 0.52 (p < 0.0001, 20mg/day). Results are limited by the post hoc nature of the analyses and the absence of an active reference in the original study. CONCLUSIONS: Vortioxetine (10 and 20mg/day) had a multi-domain beneficial effect on cognitive performance, as evidenced by improvements in measures of executive function, attention/speed of processing, and memory. The effect on the DSST may be due to improvements in several cognitive skills. Oxford University Press 2016-05-26 /pmc/articles/PMC5091828/ /pubmed/27231256 http://dx.doi.org/10.1093/ijnp/pyw054 Text en © The Author 2016. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Regular Research Article
Harrison, John E
Lophaven, Søren
Olsen, Christina K
Which Cognitive Domains are Improved by Treatment with Vortioxetine?
title Which Cognitive Domains are Improved by Treatment with Vortioxetine?
title_full Which Cognitive Domains are Improved by Treatment with Vortioxetine?
title_fullStr Which Cognitive Domains are Improved by Treatment with Vortioxetine?
title_full_unstemmed Which Cognitive Domains are Improved by Treatment with Vortioxetine?
title_short Which Cognitive Domains are Improved by Treatment with Vortioxetine?
title_sort which cognitive domains are improved by treatment with vortioxetine?
topic Regular Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091828/
https://www.ncbi.nlm.nih.gov/pubmed/27231256
http://dx.doi.org/10.1093/ijnp/pyw054
work_keys_str_mv AT harrisonjohne whichcognitivedomainsareimprovedbytreatmentwithvortioxetine
AT lophavensøren whichcognitivedomainsareimprovedbytreatmentwithvortioxetine
AT olsenchristinak whichcognitivedomainsareimprovedbytreatmentwithvortioxetine